Highlight
– In a prospective, phase IV open‑label study in China, topical cenegermin produced corneal healing in 22/26 (84.6%, 95% CI 65.1–95.6%) patients with stage 2–3 neurotrophic keratopathy (NK) at 8 weeks.
– Treatment effects were durable through 56 weeks for most patients: 20/22 (90.9%) patients who achieved initial healing remained healed at week 56, while three experienced recurrence during follow‑up.
